Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • adamwangwang47 adamwangwang47 Apr 30, 2013 4:44 PM Flag

    GAAP operating expenses in 2013, including stock-based compensation, to be between $95 and $105 million

    Aegerion continues to expect total operating expenses, excluding stock-based compensation expense, to be between $75 and $85 million in 2013. The Company expects GAAP operating expenses in 2013, including stock-based compensation, to be between $95 and $105 million. Aegerion also expects global net product sales of $15 million to $25 million for FY 2013 and 250 to 300 patients on JUXTAPID therapy globally by year-end 2013.

    average priced paid might be $10000-20000/patient eventually, including mail order plus countries of India etc where IP is not covered

    Sentiment: Strong Sell

 
AEGR
6.54+0.07(+1.08%)Feb 9 4:00 PMEST